Clinical efficacy of bromocriptine mesylate combined with human chorionic gonadotropin in treatment of hyperprolactinemia and its effect on hormone levels
Objective To investigate the clinical efficacy of bromocriptine mesylate combined with human chorionic gonadotropin in treatment of hyperprolactinemia and its effect on hormone levels.Methods A total of 144 patients with hyperprolactinemia admitted to Wuyi County First People's Hospital from January 2022 to September 2023 were enrolled in this study and divided into the observation group and control group by random number table method,with 72 patients in each group.The patients in the control group were treated with oral bromocriptine mesylate and those in the observation group with oral bromocriptine mesylate combined with human chorionic gonadotropin.The clinical efficacy,the changes of serum prolactin,luteinizing hormone,estradiol and other hormones before and after treatment,the changes of female sexual function index(FSFI)and Baker Depression Scale 2nd version(BDI-Ⅱ)score,the disease recurrence rate of patients after 3 months and 6 months,and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the control group and the observation group were 86.11%and 97.22%,respectively,the difference was statistically significant(χ2=4.455,P<0.05).After treatment,the serum level of prolactin in the observation group was(24.38±5.52)μg·L-1,which was lower than that of(28.65±4.92)μg·L-1 in the control.The serum levels of luteinogenic hormone and estradiol levels were(20.99±2.15)pg·mL-1 and(53.84±7.23)IU·L-1,respectively,which were higher than those of(18.54±2.55)pg·mL-1 and(49.63±8.23)IU·L-1 in the control,showing statistical significance(t=4.900,6.233,3.261,all P<0.001).After treatment,the FSFI score of the observation group was(32.12±1.85)points,which was higher than that of(28.54±3.25)points in the control group.BDI-Ⅱ score was(8.76±0.62)points in the observation group,which was lower than that of(10.34±0.85)points in the control group,and the difference was statistically significant(t=8.123,12.743,both P<0.001).The incidence of adverse reactions in the control group(4.17%)was similar to that in the observation group(2.78%),demonstrating no significant difference(χ2=0.000,P>0.05).The recurrence rate of the control group was 5.56%,which was higher than that of the observation group(0),but the difference was not statistically significant(χ2=2.314,P>0.05).The recurrence rate of the control group was 8.33%after 6 months,which was higher than that of the observation group(0),the difference was statistically significant(χ2=4.348,P<0.05).Conclusion Bromocriptine mesylate combined with human chorionic gonadotropin in the treatment of hyperprolactinemia has significant clinical effect since it can improve the hormone level,sexual function and adverse psychology of patients.Meanwhile,the disease recurrence rate and adverse reactions of patients after discharge are low.
NETL
NSTL
万方数据
